公开(公告)号：US20190307735A1

公开(公告)日：2019-10-10

申请号：US16444843

申请日：2019-06-18

Applicant: MERCK SHARP & DOHME CORP

Inventor： Jason M. Cox ,  Lijun Ma ,  Xiaoyan Zhou ,  Robin E. Haimbach ,  Paul J. Coleman ,  Haihong Zhou ,  David E. Kelley ,  Selwyn Aubrey Stoch ,  Le T. Duong ,  Maarten Hoek

IPC: A61K31/444 ,  A61K31/55 ,  A61K31/4375 ,  A61P13/12 ,  A61K31/401 ,  A61K31/506 ,  A61K31/4178

Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.

公开(公告)号：US20180353507A1

公开(公告)日：2018-12-13

申请号：US15780462

申请日：2016-12-13

Applicant: Merck Sharp & Dohme Corp.

Inventor： David E. Kelley ,  Ping Liu ,  Harold B. Wood ,  Scott D. Edmondson ,  Hideo Makimura ,  Xiaoyan Li ,  Timothy Joseph Kowalski

IPC: A61K31/506 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  A61P1/18

CPC classification number: A61K31/506 ,  A61K31/00 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  A61P1/18 ,  C12Q1/02 ,  G01N33/74 ,  G01N2333/726 ,  G01N2800/042

Abstract: Use of a GPR119 agonist in the prevention or treatment of hypoglycemia is disclosed, addition, pharmaceutical compositions and combinations of a GPR1 19 agonist with insulin, insulin analog, insulin secretagogue or or other drug(s) that reduces plasma glucose levels to below 70 mg/dL described herein.

公开(公告)号：US20170254798A1

公开(公告)日：2017-09-07

申请号：US15060786

申请日：2016-03-04

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yingjun Mu ,  Ruojing Yang ,  Xinghai Li ,  Margaret Wu ,  Qing Dallas-yang ,  Yuli Chen ,  Ge Dai ,  Songnian Lin ,  David E. Kelley ,  Mark Erion

IPC: G01N33/50 ,  G01N33/74

CPC classification number: G01N33/502 ,  G01N33/5044 ,  G01N33/74 ,  G01N2333/62 ,  G01N2333/70596 ,  G01N2400/00 ,  G01N2500/04 ,  G01N2500/20

Abstract: Methods for identifying drug-saccharide conjugates that bind the mannose receptor, C type 1, (MRC1) and may be taken up by cells expressing MRC1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the MRC1 receptor and may be taken up by cells expressing the MRC1 and use of such conjugates for treatment of diabetes are described.

公开(公告)号：US20170248580A1

公开(公告)日：2017-08-31

申请号：US15595115

申请日：2017-05-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yingjun Mu ,  Ruojing Yang ,  Xinghai Li ,  Margaret Wu ,  Qing Dallas-yang ,  Yuli Chen ,  Ge Dai ,  Songnian Lin ,  David E. Kelley ,  Mark Erion

IPC: G01N33/50 ,  G01N33/569

CPC classification number: G01N33/5055 ,  G01N33/74 ,  G01N2333/70596 ,  G01N2500/04

Abstract: Methods for identifying drug-saccharide conjugates that bind the mannose receptor, C type 1, (MRC1) and may be taken up by cells expressing MRC1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the MRC1 receptor and may be taken up by cells expressing the MRC1 and use of such conjugates for treatment of diabetes are described.